ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
4 announcements with these filters
Aurobindo Pharma received USFDA final approval for its first MDI product, Beclomethasone Dipropionate HFA Inhalation Aerosol. The US market for this segment is estimated at US$301 million.
Aurobindo Pharma's subsidiary, CuraTeQ Biologics, received ANVISA (Brazil) approval for its biosimilars manufacturing facility in Hyderabad. This approval enables supply to Brazilian and Latin American markets.
Aurobindo Pharma received final US FDA approval for Tofacitinib Tablets used in treating rheumatoid arthritis. The product will be manufactured by its subsidiary and launched immediately.
Aurobindo Pharma subsidiary CuraTeQ received CDSCO marketing approval for Bevqolva, a bevacizumab biosimilar. The authorisation permits domestic manufacturing and marketing for metastatic colorectal cancer treatment.